Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Keytruda — provider of 35% of Merck’s revenue over the last three years — and Bristol’s Opdivo will both become potential candidates for negotiations in 2028.
Specifically, Bristol-Myers Squibb is exposed to potential IRA price negotiation pressures for its major drugs including Eliquis, Opdivo, and Orencia; although I do not yet model IRA-driven price pressure as I would like to await further developments.